SCHEMBL6369145

SCHEMBL6369145

Nc1ccn(C2O[C@H](COC(=O)c3ccccc3)[C@@H](OC(=O)c3ccccc3)C2(F)F)c(=O)n1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 1/20 0.56
▸ PDE3A Q14432 1/20 0.56
▸ SLC29A1 Q99808 1/20 0.56
▸ POLA1 P09884 2/20 0.51
▸ ALDH1A1 P00352 3/20 0.42
▸ POLB P06746 3/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ST6GAL1 P15907 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ MDM2 Q00987 1/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ ITGB3 P05106 1/20 0.36
▸ ITGAV P06756 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27930788 1.00 PDE4D (0.56) PDE4DPDE3ASLC29A1POLA1ALDH1A1
SCHEMBL17841790 1.00 PDE4D (0.56) PDE4DPDE3ASLC29A1POLA1ALDH1A1
SCHEMBL23227420 1.00 PDE4D (0.56) PDE4DPDE3ASLC29A1POLA1ALDH1A1
SCHEMBL23467204 1.00 PDE4D (0.56) PDE4DPDE3ASLC29A1POLA1ALDH1A1
Hydrochloric Acid SCHEMBL2689516 0.99 PDE4D (0.55) PDE4DPDE3ASLC29A1POLA1ALDH1A1
SCHEMBL10048580 0.91 PDE3A (0.66) PDE4DPDE3ASLC29A1POLA1POLB
SCHEMBL2784191 0.91 PDE3A (0.66) PDE4DPDE3ASLC29A1POLA1POLB
SCHEMBL15849797 0.91 PDE3A (0.66) PDE4DPDE3ASLC29A1POLA1POLB
SCHEMBL2784182 0.91 PDE3A (0.66) PDE4DPDE3ASLC29A1POLA1POLB
SCHEMBL10017432 0.91 PDE3A (0.66) PDE4DPDE3ASLC29A1POLA1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271996-A1 PROCESS FOR PREPARING CEDAZURIDINE SCINOPHARM TAIWAN, LTD. (TW) 2023-08-31 — — US disclosed
US-8168766-B2 Process of making 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides and intermediates therefor ScnioPharm Taiwan Ltd. (TW) 2012-05-01 — — US disclosed
US-20100056771-A1 Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor SCINOPHARM TAIWAN LTD. (TW) 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056771-A1 Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor SAMHD1, DPYD, GARS1 PDE4D 4099/4885PDE3A 3703/4885SLC29A1 6/4885
US-20230271996-A1 PROCESS FOR PREPARING CEDAZURIDINE DUT, CCNB1, EZH1 PDE4D 2766/4885PDE3A 2941/4885SLC29A1 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback